News2020-02-23T23:18:18-05:00
Page-TitleNEWS

Virpax Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on Epoladerm for the Management of Osteoarthritis of the Knee

505(b)(2) Regulatory Pathway and Proposed Study Design Is Acceptable Virpax to Finalize IND and Prepare for Phase I Human Study Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, today announced that it has successfully completed a [...]

March 19th, 2020|Press Release|

Virpax Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on NES100 for the Management of Acute and Chronic Pain

Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems today announced that it has successfully completed a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) for NES100 which uses the Nanomerics [...]

March 2nd, 2020|Press Release|

Virpax Pharmaceuticals Selected for Two Presentations at the 2020 Special Operations Medical Association Exhibition

Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that their Chief Medical Officer Jeffrey Gudin, M.D., will present two abstracts at the 2020 Special Operations Medical Association’s Training, Education, Scientific Assembly and Exhibition (SOMA) being held May 11-15, 2020, at the [...]

February 5th, 2020|Press Release|

Michèle C. Linde Promoted to EVP, Global Corporate Governance, Chief Legal Officer & Corporate Secretary for Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that Michèle C. Linde has been promoted to EVP, Global Corporate Governance, Chief Legal Officer & Corporate Secretary effective immediately. “This promotion reflects our company's commitment to excellence,” said Anthony P. Mack, [...]

October 20th, 2019|Press Release|

Virpax Pharmaceuticals Announces the Appointment of Three Independent Directors

Virpax Pharmaceuticals Inc. (“Virpax”) a company specializing in developing pharmaceutical products for pain management, is pleased to announce the appointment of three independent directors: Eric Floyd, PhD, Jerrold Sendrow, CFP and Thani Jambulingam, PhD, at their Annual General Meeting of the Shareholders held on Monday, September 9, 2019 [...]

September 10th, 2019|Press Release|

Virpax Pharmaceuticals Announces the Appointment of Three Independent Directors

Virpax Pharmaceuticals Inc. (“Virpax”) a company specializing in developing pharmaceutical products for pain management, is pleased to announce the appointment of three independent directors: Eric Floyd, PhD, Jerrold Sendrow, CFP and Thani Jambulingam, PhD, at their Annual General Meeting of the Shareholders held on Monday, September 9, 2019 [...]

September 10th, 2019|Press Release|

Virpax Pharmaceuticals Announces the Proposed Development of A Long Acting Naloxone and Naltrexone Liposomal Delivery To Reverse Opioid Related Respiratory Depression

Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, announced today that it proposes the development of a naloxone/naltrexone IP-protected formulation (RES202) consisting of liposomes embedded in a hydrogel or a lyophilized formulation suitable for intramuscular delivery by first responders with minimal training [...]

August 13th, 2019|Press Release|

Virpax Pharmaceuticals to Present at the 2019 Military Health System Research Symposium

Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that their Chief Medical Officer Jeffrey Gudin, M.D., will present two posters at the 2019 Military Health System Research Symposium (MHSRS) being held August 19-22, 2019, at the Gaylord Palms Resort and [...]

August 6th, 2019|Press Release|

Virpax Pharmaceuticals Announces Appointment of Michèle C. Linde, EVP, General Counsel

Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced the appointment of Michèle C. Linde as the Company’s Executive Vice President, General Counsel and Corporate Secretary. Ms. Linde has more than 25 years of in-house and private legal practice experience with [...]

June 11th, 2019|Press Release|

Virpax Pharmaceuticals Selected for Two Presentations at the 2019 Military Health System Research Symposium

Virpax Pharmaceuticals, Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management, today announced that their Chief Medical Officer Jeffrey Gudin, M.D., will present two abstracts at the 2019 Military Health System Research Symposium (MHSRS) being held August 19-22, 2019, at the Gaylord Palms Resort and [...]

June 3rd, 2019|Press Release|

Virpax Pharmaceuticals to Present at ThinkEquity Conference

Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, today announced that Anthony P. Mack, Chairman and CEO of Virpax will be presenting at the ThinkEquity Conference at 12:30 p.m. ET on Thursday, May 2, 2019 in [...]

April 24th, 2019|Press Release|

Virpax Pharmaceuticals Licenses Molecular Envelope Technology (MET) Intranasal Formulation From Nanomerics Ltd.

Virpax to Develop a Non-Opioid Molecular Envelope Technology (MET) Intranasal Formulation for the Management of Chronic Pain Virpax Pharmaceuticals Inc. (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with Nanomerics Ltd. Under the agreement, [...]

April 16th, 2019|Press Release|

Virpax Pharmaceuticals Announces Successful Pre-IND Meeting for LBL100

505(b)(2) Regulatory Pathway and Proposed Study Design Is Acceptable Virpax to Finalize IND and Prepare for Phase 1 Human Study Virpax Pharmaceuticals ("Virpax"), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, completed a successful pre-Investigational New Drug ("pre-IND") Meeting with [...]

December 27th, 2018|Press Release|

Virpax Pharmaceuticals Reports Pre-IND Guidance From FDA for DSF100

505(b)(2) Regulatory Pathway and Proposed Study Design Is Acceptable Virpax to Finalize IND and Prepare for Phase 1 Human Study Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, received a written response from the US Food and [...]

September 12th, 2018|Press Release|

Virpax Pharmaceuticals Licenses Liposome Drug Delivery Technology From LipoCure

Virpax to Develop a Long-Acting Liposomal Gel (Lipogel) for Post-Operative Pain Virpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with LipoCure to develop pain management products using its liposome drug delivery technology. [...]

June 4th, 2018|Press Release|

Virpax Pharmaceuticals Licenses Liposome Drug Delivery Technology From LipoCure

Virpax to Develop a Long-Acting Liposomal Gel (Lipogel) for Post-Operative PainVirpax Pharmaceuticals (“Virpax”), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems, signed a technology license agreement with LipoCure to develop pain management products using its liposome drug delivery technology. The first [...]

June 4th, 2018|Press Release|